Inicio・Lista de Acciones・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Abierto

SectorSanidad

13.34 -0.74

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

13.14

Máximo

13.61

Métricas clave
By Trading Economics
Ingresos	-1.2M -13M
Ventas	-1.5M 17M
BPA	-0.45
Margen de beneficios	-76.292
Empleados	120
EBITDA	-958K -8.6M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+49.03% upside

Dividendos
By Acuity
Próximas Ganancias	7 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-39M 383M
Apertura anterior	14.08
Cierre anterior	13.34

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

60 / 340 Clasificación en Healthcare

ENANTA PHARMACEUTICALS INC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20 jul 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Comparación entre iguales

Cambio de precio

ENANTA PHARMACEUTICALS INC previsión

Precio Objetivo

By TipRanks

49.03% repunte

Estimación a 12 Meses

Media 20 USD 49.03%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ENANTA PHARMACEUTICALS INC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para ENANTA PHARMACEUTICALS INC Dist en los últimos 3 meses.

Sentimiento

By Acuity

60 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.